GT200600125A - Nueva sal y polimorfos del inhibidor de la dpp-iv - Google Patents

Nueva sal y polimorfos del inhibidor de la dpp-iv

Info

Publication number
GT200600125A
GT200600125A GT200600125A GT200600125A GT200600125A GT 200600125 A GT200600125 A GT 200600125A GT 200600125 A GT200600125 A GT 200600125A GT 200600125 A GT200600125 A GT 200600125A GT 200600125 A GT200600125 A GT 200600125A
Authority
GT
Guatemala
Prior art keywords
polymorphes
dpp
inhibitor
new salt
salt
Prior art date
Application number
GT200600125A
Other languages
English (en)
Inventor
Stefan Abrecht
Andre Gerard Bubendorf
Stephan Goetzoe
Olaf Grassmann
Francois Montavon
Regina Moog
Franziska Rohrer
Armin Ruf
Michelangelo Scalone
Urs Schwitter
Shaoning Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200600125A publication Critical patent/GT200600125A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A NUEVA SAL Y POLIMORFOS DEL INHIBIDOR DE LA DPP-IV. ESTE COMPUESTO Y SUS FORMAS POLIMÓRFICAS POSEEN PROPIEDADES SUPERIORES SI SE COMPARAN CON LOS COMPUESTOS CONOCIDOS ANTERIORMENTE Y PUEDEN UTILIZARSE COMO MEDICAMENTOS EN CUADROS DE DIABETES, COLITIS ULCEROSA, OBESIDAD, ENTRE OTROS DESCRITOS EN EL EXPEDIENTE. T2006
GT200600125A 2005-03-22 2006-03-22 Nueva sal y polimorfos del inhibidor de la dpp-iv GT200600125A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05102251 2005-03-22

Publications (1)

Publication Number Publication Date
GT200600125A true GT200600125A (es) 2007-03-16

Family

ID=36406081

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600125A GT200600125A (es) 2005-03-22 2006-03-22 Nueva sal y polimorfos del inhibidor de la dpp-iv

Country Status (17)

Country Link
US (1) US7772264B2 (es)
EP (1) EP1888571A2 (es)
JP (1) JP5043825B2 (es)
KR (1) KR20070113305A (es)
CN (1) CN101146801A (es)
AR (1) AR055570A1 (es)
AU (1) AU2006226447B2 (es)
BR (1) BRPI0609580A2 (es)
CA (1) CA2600203C (es)
DO (1) DOP2006000066A (es)
GT (1) GT200600125A (es)
IL (1) IL185768A0 (es)
MX (1) MX2007011546A (es)
PA (1) PA8666701A1 (es)
PE (1) PE20061109A1 (es)
TW (1) TW200700415A (es)
WO (1) WO2006100181A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20110190322A1 (en) 2008-08-14 2011-08-04 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
CZ2008512A3 (cs) 2008-08-26 2010-03-10 Zentiva, A. S Zpusob prípravy vysoce cistého vildagliptinu
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
TWI466672B (zh) 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
AU2010212823B2 (en) 2009-02-13 2016-01-28 Boehringer Ingelheim International Gmbh Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
CN102753161A (zh) 2009-11-27 2012-10-24 贝林格尔.英格海姆国际有限公司 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
JP2013523819A (ja) 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
EP3124041A1 (en) 2010-06-24 2017-02-01 Boehringer Ingelheim International GmbH Diabetes therapy
KR101871011B1 (ko) 2010-09-22 2018-06-25 아레나 파마슈티칼스, 인크. Ｇｐｒ１１９ 수용체의 조절제 및 그와 관련된 장애의 치료
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN103787944A (zh) * 2012-11-01 2014-05-14 天津药物研究院 1-(2-氯乙酰基)-2-(s)-腈基吡咯烷的制备方法
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
CN104262227B (zh) * 2014-09-16 2018-09-18 东北制药集团股份有限公司 一种制备(s)-1-(2-氯乙酰基)吡咯烷-2-甲腈的方法
CA2979033A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
CN106699627A (zh) * 2016-12-29 2017-05-24 青岛黄海制药有限责任公司 一种多相复式非连续生产法制备1‑(2‑氯乙酰基)‑2‑(s)‑氰基吡咯烷的方法
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07247246A (ja) * 1994-03-09 1995-09-26 Daicel Chem Ind Ltd １−フェニル−３−ブチン誘導体とその製造方法
TW492957B (en) * 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
DK0921125T3 (da) * 1997-12-05 2002-05-13 Hoffmann La Roche 1,3,8-triazaspiro[4.5]decan-4-on-derivater
DE19755436A1 (de) 1997-12-13 1999-06-24 Beiersdorf Ag Verfahren zur zumindest partiellen direkten Beschichtung eines dehnfähigen Trägermaterials mit einer Haftklebemasse
RU2180663C2 (ru) * 1998-03-30 2002-03-20 Джапан Тобакко Инк. Способ получения изоксазолидиндионового соединения, способ получения оксазолилэтанольного соединения (варианты), способ получения аспартатного соединения, способ получения оксазолилацетатного соединения, способ получения метансульфонатного соединения, способ получения бензилиденового соединения
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
WO2003040114A1 (en) * 2001-11-06 2003-05-15 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
JP3746063B2 (ja) * 2002-08-29 2006-02-15 大正製薬株式会社 ４−フルオロ−２−シアノピロリジン誘導体ベンゼンスルホン酸塩
GB0313661D0 (en) * 2003-06-13 2003-07-16 Avecia Ltd Process

Also Published As

Publication number Publication date
TW200700415A (en) 2007-01-01
AU2006226447A1 (en) 2006-09-28
AU2006226447B2 (en) 2009-07-16
US20060217428A1 (en) 2006-09-28
IL185768A0 (en) 2008-01-06
CA2600203A1 (en) 2006-09-28
JP5043825B2 (ja) 2012-10-10
JP2008534470A (ja) 2008-08-28
DOP2006000066A (es) 2006-09-30
CN101146801A (zh) 2008-03-19
AR055570A1 (es) 2007-08-22
MX2007011546A (es) 2007-10-19
US7772264B2 (en) 2010-08-10
BRPI0609580A2 (pt) 2010-04-20
EP1888571A2 (en) 2008-02-20
PE20061109A1 (es) 2006-10-13
WO2006100181A2 (en) 2006-09-28
WO2006100181A3 (en) 2006-11-30
PA8666701A1 (es) 2006-12-07
KR20070113305A (ko) 2007-11-28
CA2600203C (en) 2012-12-04

Similar Documents

Publication Publication Date Title
GT200600125A (es) Nueva sal y polimorfos del inhibidor de la dpp-iv
DE502007004290D1 (de) Carbazol-derivate für organische elektrolumineszenzvorrichtungen
CR9399S (es) Contenedor
NI200700169A (es) Derivados del pirimidinil y piridinil sustituidos como moduladores del metabolismo y el tratamiento de desordenes relacionados con el mismo.
ECSP10010722A (es) Compuestos orgánicos
TW201129567A (en) Materials for organic electroluminescent devices
CR9611S (es) Contenedor
NI201100049A (es) Compuestos orgánicos.
CO6670585A2 (es) Promotores de apotosis n-acilsufonamidas
NI201200023A (es) Derivados de 5-fluoropirimidinona
PL2126020T3 (pl) Hydrofobowo modyfikowane polialkilenoiminy jako inhibitory przenoszenia barwnika
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CL2008002369A1 (es) Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
EA201000272A1 (ru) Трициклические мостиковые производные циклопентадиенона, как гербициды
CL2007002890A1 (es) Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad.
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona
ECSP10010058A (es) Derivados de quinazolinadiona, su preparación y sus aplicaciones terapéuticas
CR9619S (es) Contenedor y cierre
ECSP21011232A (es) Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende
GT200700074A (es) Fungicidas
CL2009000599A1 (es) Compuestos derivados de 4,5-dihidro-1h-pirazol(4,3-g)benzotiazol sustituidos; composicion farmaceutica; utiles para el tratamiento y prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes, entre otras.
DOP2020000077A (es) Nuevo derivado de fenilpiridina y composición farmacéutica que lo contiene
CR9613S (es) Contenedor
CR9397S (es) Contenedor
CR11449A (es) Productos intermedios gsm